Investors
Share Information
Xintela AB (publ) is traded on Nasdaq First North Growth Market as of 22 March 2016.
Short name for the company’s common share: XINT (ISIN code: SE0007756903)
After the latest subscription period for warrants of series TO3 which ended on 5 June 2025, the share capital amounts to SEK 20,986,940.43 divided into 699,564,681 shares. All issued shares are fully paid. The company’s share capital is expressed in Swedish kronor and is divided into the Company’s issued shares with a quota value of SEK 0.03 per share.
The company’s company name and trading name is Xintela AB (publ) and the company has corporate registration number 556780-3480. The board of directors has its registered office in Lund and the company’s registered address is Medicon Village,
223 81 Lund, Sweden.
Financial Calendar
- 27 Feb, 2026
- — Interim Report Q4, 2025
- 22 May, 2026
- — Annual General Meeting
- 29 May, 2026
- — Interim Report Q1
- 28 Aug, 2026
- — Interim Report Q2
- 27 Nov, 2026
- — Interim Report Q3
- 26 Feb, 2027
- — Interim Report Q4
Analyses
Share issues
Management and board
Xintela’s management and board have extensive experience from the Life Science industry, regarding research and development of companies and medical products in both preclinical and clinical phases. The board also has broad experience in both cell therapy and cancer therapy, and possesses great competence in areas such as economics and law.
Management
Evy Lundgren-Åkerlund
Chief Executive Officer since 2009. Doctor of Medical Sciences, Associate Professor.
Gunnar Telhammar
Hired to the company as Chief Financial Officer since 2013. Master of Science in Economics from Lund University.
Peter Ekolind
Chief Operating Officer since August 2020. MBA.COO & VP Commercial Manufacturing since 2025, Executive MBA.
Gregory Batcheller
Chairman of the Board since 2011. LL.M, J.D., B.Sc. (Econ.)
Camilla Wennersten
Director of Clinical Development since 2021. PH.D.
Liselotte Theorell
Director of Quality Management since 2017, QP.
Lucienne Vonk
CSO since 2024. Ph.D., Associate Professor
Board
Gregory Batcheller
Chairman of the Board since 2011. LL.M, J.D., B.Sc. (Econ.)
Maarten de Château
Board member since 2021. Physician and Doctor of Medical Science.
Thomas Eldered
Board member since 2022. Master of Science in Industrial Economics.
Lars Hedbys
Board member since 2021. Technical Doctor in Applied Biochemistry.
Hans-Joachim Simons
Board member since 2022. Medical doctor with specialist expertise in orthopedics and MBA.
Corporate Governance
Good corporate governance is critical to ensure that a company is managed in the correct manner. At Xintela, we are eager to have a good and clear corporate governance such that our investors trust the company and that the decisions that are made are well considered.
The Board and The Management Team
The Board are accountable for the company’s organisation and management and are the highest administrative structure below the General Meeting. The Management Team are appointed by the Board and their role is to manage the day to day operations of the company. Within the framework set out by the Board, the Management team can also manage, for example, company-wide matters and those of a strategic nature.
Read more about Xintela’s board and management team here.
Auditors
Öhrlings PricewaterhouseCoopers AB, 113 97 Stockholm have been the company’s auditors since 2010. The company’s primary auditor, since 2015, is Ola Bjärehäll, Box 2138, 22002 Lund.
Articles of association
The Articles of Association are the regulations by which a limited company are governed. Xintela’s Articles of Association can be downloaded here.
Owner List
PDMR transactions
Transactions performed by persons in senior positions are registered in accordance with EU rules on market abuse (MAR) in Finansinspektionen’s transparency register.
IR-contact
For any IR-related questions, please contact:
Certified Adviser
The Company’s Certified Adviser is:
Tapper Partners AB
Phone: +46 (0)70 44 010 98
E-mail: ca@tapperpartners.se
